首页> 外文期刊>Journal of tissue engineering and regenerative medicine >Cell-assisted lipotransfer: Friend or foe in fat grafting? Systematic review and meta-analysis
【24h】

Cell-assisted lipotransfer: Friend or foe in fat grafting? Systematic review and meta-analysis

机译:细胞辅助Lipotransfer:脂肪嫁接的朋友或敌人? 系统审查和荟萃分析

获取原文
获取原文并翻译 | 示例
       

摘要

Autologous fat grafting is a common procedure for soft-tissue reconstruction but is associated with a graft resorption rate ranging from 20% to 80%. To improve the fat graft survival rate, a new technique, called cell-assisted lipotransfer (CAL), was developed. With CAL, fat is injected along with adipose-derived stromal cells that are assumed to improve fat survival rate. We conducted an evidence-based meta-analysis to evaluate the efficacy and safety of CAL as compared with conventional autologous fat grafting (non-CAL). The databases MEDLINE (via PubMed), Cochrane Library, EBSCO, Web of Science, and EMBASE were searched for reports of clinical trials, case series, and cohorts available from 2008 to 2016. We conducted a meta-analysis of the efficacy of CAL with data analysis concerning fat survival rate. The incidence of complications and the need for multiple procedures were evaluated to determine the safety of CAL. We identified 25 studies (696 patients) that were included in the systematic review; 16 studies were included in the meta-analysis to evaluate the efficacy of CAL. The fat survival rate was significantly higher with CAL than non-CAL (64% vs. 44%, p.0001) independent of injection site (breast and face). This benefit of CAL was significant for only injection volumes 100ml (p=.03). The two groups did not differ in frequency of multiple procedures after fat grafting, but the incidence of complications was greater with CAL than non-CAL (8.4% vs. 1.5%, p=.0019). The CAL method is associated with better fat survival rate than with conventional fat grafting but only for small volumes of fat grafting (100ml). Nonetheless, the new technique is associated with more complications and did not reduce the number of surgical procedures needed after the first fat grafting. More prospective studies are required to draw clinical conclusions and to demonstrate the real benefit of CAL as compared with common autologous fat grafting.
机译:自体脂肪移植是软组织重建的常见程序,但与接枝振荡速率相关的常见程序,范围为20%至80%。为了提高脂肪移植存活率,开发了一种叫做细胞辅助Lipot转移(CAL)的新技术。用Cal,脂肪与脂肪衍生的基质细胞一起注射,所述衍生的基质细胞被假定提高脂肪存活率。我们进行了基于证据的荟萃分析,以评估CAL的功效和安全性与常规的自体脂肪移植(非CAL)相比。临床试验,案例系列和队列的报告,数据库Medline(通过Pubmed),Cochrane图书馆,EBSCO,科学网站和Embase的报告,从2008年到2016年提供了临床试验,案例系列和群组。我们对CAL的疗效进行了荟萃分析关于脂肪存活率的数据分析。评估并发症的发生率和多种程序的需求以确定CAL的安全性。我们确定了25项研究(696名患者),这些研究包括在系统审查中;在Meta分析中包含16项研究以评估CAL的功效。与注射部位(乳房和脸部)无关,脂肪存活率明显高于非CAL(64%vs.44%,P& .0001)。 Cal的这种益处仅对注射体积且仅注射体积& 100ml(p = .03)很重要。两组在脂肪移植后多程序的频率没有差异,但是,CAL的并发症发生率大于非CAL(8.4%vs.1.5%,P = .0019)。 CAL方法与常规脂肪移植的更好的脂肪存活率相关,但仅用于小体积的脂肪移植(& 100ml)。尽管如此,新技术与更多并发症相关,并没有减少第一次脂肪嫁接后所需的外科手术的数量。需要更多的前瞻性研究来吸引临床结论,并展示CAL与常见的自体脂肪移植相比的真正好处。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号